Medpace Holdings, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Medpace is a global contract research organization providing clinical development services to pharmaceutical, biotechnology, and medical-device companies. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance
- Q2 revenue: $460.9 million, up 31.2% from $351.2 million. Growth was driven by Oncology, Metabolic, AVAI, Cardiology, and other therapeutic areas.
- Q2 operating income: $78.4 million versus $60.2 million; operating margin was approximately 17.0% versus 17.1%. Net income: $61.1 million versus $49.4 million; diluted EPS was $1.93 versus $1.46.
- First-half revenue: $894.9 million, up 31.2%. Operating income was $164.6 million versus $124.4 million; operating margin was approximately 18.4% versus 18.2%. Net income was $134.0 million versus $110.7 million; diluted EPS was $4.20 versus $3.16.
- Costs and margins: Q2 total direct costs rose 33.4% to $336.6 million, faster than revenue, largely due to higher reimbursed out-of-pocket expenses and personnel costs. SG&A rose 18.6% to $39.4 million. Reimbursed expenses can fluctuate with study initiation and closeout timing.
- Cash flow, first half: Operating cash flow was $162.6 million versus $142.9 million. Capital expenditures were $18.0 million versus $20.5 million. Cash increased $10.9 million to $39.1 million.
- Liquidity and debt: Cash was $39.1 million; short-term debt under the credit facility was $55.0 million. The $150.0 million revolving facility had $94.8 million available to borrow; its stated interest rate was 6.3% at quarter-end. Operating lease liabilities totaled $159.4 million.
- Balance sheet: Accounts receivable and unbilled balances were $275.1 million; advanced billings were $490.6 million. Total assets were $1.407 billion and shareholders’ equity was $391.1 million.
Business momentum and changes from prior periods
- Net new business awards were $574.8 million in Q2 and $1.131 billion in the first half, compared with $450.6 million and $873.6 million, respectively, in 2022.
- Backlog was $2.572 billion at June 30, up 18.6% from $2.168 billion a year earlier. Medpace expected approximately $1.410–$1.430 billion to convert to revenue over the following 12 months. The filing cautions that awards and backlog are not necessarily reliable predictors of future revenue.
- First-half revenue growth was broad, with notable increases in Oncology and Metabolic. CNS revenue was approximately flat for the first half compared with 2022.
- First-half share repurchases were $144.0 million, compared with $800.7 million in the prior-year period. The company reported $308.8 million remaining under its $500 million repurchase authorization.
Outlook, risks, contingencies, and notable items
- The filing provides backlog conversion expectations but no formal revenue or earnings guidance. Management described plans to fund operations and growth with operating cash flow, existing cash, and, if needed, credit-facility borrowings; it also cited potential selective bolt-on acquisitions and investments.
- Customers generally may cancel contracts on about 30 days’ notice. Revenue and backlog conversion depend on study execution, scope changes, cancellations, and timing; clinical-trial outcomes, patient enrollment, and regulatory hurdles can affect projects.
- Other cited uncertainties include competition, economic conditions and inflation-related pricing pressure, foreign-exchange movements, and the timing of receivable collections and customer billings. Foreign-exchange gains and losses contributed to the year-over-year change in miscellaneous income or expense.
- Legal proceedings were described as ordinary-course matters; the company said recognized reserves and potential additional losses were immaterial at June 30, 2023. Minimum purchase commitments for project supplies were $17.1 million, expiring through 2029.
- Related-party matters warrant attention: certain executives, including the CEO, have relationships with customers LIB Therapeutics and CinRx; the CEO owns entities that lease campus office space to Medpace and controls a private aviation charter company used for travel. Related-party lease right-of-use assets were included in total lease assets.
- The company reported effective disclosure controls and no significant change in previously disclosed risk factors. It upgraded its accounting ERP platform to a cloud-based version during the quarter.
Important facts for investors to verify
- Whether award growth and backlog convert to recognized revenue on expected timelines, given cancellation rights and project uncertainty.
- How much of revenue growth reflects service activity versus reimbursed out-of-pocket expenses, and the effect of those costs on operating margins.
- Receivable collection, advanced-billing trends, operating cash generation, and continued access to the credit facility.
- The pace and funding of share repurchases relative to liquidity, debt repayment, capital investment, and lease obligations.
- Governance and commercial terms for material related-party customers, leases, and travel arrangements.